


WHAT IS CLAIMED IS:

1. A compound of Formula (I), or a pharmaceutically acceptable salt thereof, having the structure:



wherein:

R¹ is selected from the group consisting of hydrogen, halogen, a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl, a substituted or unsubstituted C₃-C₆ cycloalkyl, a substituted or unsubstituted C₁-C₆ alkoxy, an unsubstituted mono-C₁-C₆ alkylamine and an unsubstituted di-C₁-C₆ alkylamine;

each R² is independently selected from the group consisting of halogen, a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl and a substituted or unsubstituted C₃-C₆ cycloalkyl; or

when m is 2 or 3, each R² is independently selected from the group consisting of halogen, a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl and a substituted or unsubstituted C₃-C₆ cycloalkyl, or two R² groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted C₃-C₆ cycloalkyl or a substituted or unsubstituted 3 to 6 membered heterocyclyl;

R³ is hydrogen or halogen;

R⁴ is selected from the group consisting of NO₂, S(O)R⁶, SO₂R⁶, halogen, cyano and an unsubstituted C₁-C₆ haloalkyl;

R⁵ is a substituted or unsubstituted C₁-C₆ alkylene, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-, a substituted or unsubstituted -(C₁-C₆ alkylene)-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-Het-, a substituted or unsubstituted -(C₁-C₆ alkylene)-N(C₁-C₆ alkyl)-Het-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-N(C₁-C₆ alkyl)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-N(C₁-C₆ alkyl)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-(C=O)-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-(C=O)-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-(C=O)-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-(C=O)-N(C₁-C₆ alkyl)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-(C=O)-N(C₃-C₆ cycloalkyl)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-N(C₃-C₆ cycloalkyl)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-Het-N(C₃-C₆ cycloalkyl)- or a substituted or unsubstituted -(C₁-C₆ alkylene)-N(C₃-C₆ cycloalkyl)-Het-, where Het is a substituted or unsubstituted 3 to 10 membered heterocyclyl;

R⁶ is a substituted or unsubstituted C₁-C₆ alkyl, a substituted or unsubstituted C₁-C₆ haloalkyl or a substituted or unsubstituted C₃-C₆ cycloalkyl;

R⁷ is absent, a substituted or unsubstituted C₁-C₆ alkylene, -(C=O)-, -(C=S)-, -(C=O)-NH-, -(C=O)-N(C₁-C₆ alkyl)-, -(C=O)-N(C₃-C₆ cycloalkyl)-, -(C=O)-O-, -(C=S)-NH- or a substituted or unsubstituted (C₁-C₆ alkylene)-NH-;

R⁸ is absent, a substituted or unsubstituted C₁-C₆ alkylene, a substituted or unsubstituted -(C₁-C₆ alkylene)-(C₆-C₁₂ aryl)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-(C₃-C₁₀ cycloalkyl)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-(C₃-C₁₀ heterocyclyl)- or a substituted or unsubstituted -(C₁-C₆ alkylene)-(5 to 10 membered heteroaryl)-;


m is 0, 1, 2 or 3;


n is 0, 1, 2, 3, 4 or 5;


X¹ is -O- or -NH-;

R^9 is a substituted or unsubstituted C_1 - C_{10} alkylene, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-O-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-(C=O)NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-O-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH(C=O)-(C_1-C_6 \text{ alkylene})-NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH(C=O)-(C_1-C_6 \text{ alkylene})-O-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH(C=O)-(C_1-C_6 \text{ alkylene})-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-NH(C=O)-(C_1-C_6 \text{ alkylene})-NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-NH(C=O)-(C_1-C_6 \text{ alkylene})-O-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-NH(C=O)-(C_1-C_6 \text{ alkylene})-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-(C=O)NH-(C_1-C_6 \text{ alkylene})-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-(C=O)NH-(C_1-C_6 \text{ alkylene})-NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-(C=O)NH-(C_1-C_6 \text{ alkylene})-O-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH(C=O)-(C_1-C_6 \text{ alkylene})-(C=O)NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-(C=O)NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-(C_1-C_6 \text{ alkylene})-(C=O)NH-(C_1-C_6 \text{ alkylene})-$ or a substituted or an unsubstituted $-(C_1-C_6 \text{ alkylene})-C\equiv C-$;

R^{10} is selected from the group consisting of:







2. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is halogen.

3. The compound of any one of Claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R^1 is fluoro.

4. The compound of any one of Claims 1-2, or a pharmaceutically acceptable salt thereof, wherein R^1 is chloro.

5. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a substituted or unsubstituted C_1 - C_6 alkyl.

6. The compound of Claim 1 or 5, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted C_1 - C_6 alkyl.
7. The compound of any one of Claims 1 or 5-6, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted methyl or an unsubstituted ethyl.
8. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a substituted or unsubstituted C_1 - C_6 haloalkyl.
9. The compound of Claim 1 or 8, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted $-CHF_2$, $-CF_3$, $-CH_2CF_3$, $-CF_2CF_3$ or $-CF_2CH_3$.
10. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is hydrogen.
11. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a substituted or unsubstituted C_3 - C_6 cycloalkyl.
12. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted C_3 - C_6 cycloalkyl.
13. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is a substituted or unsubstituted C_1 - C_6 alkoxy.
14. The compound of Claim 1 or 13, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted C_1 - C_6 alkoxy.
15. The compound of any one of Claim 1 or 13-14, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted methoxy or an unsubstituted ethoxy.
16. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted mono- C_1 - C_6 alkylamine.
17. The compound of Claim 1 or 16, or a pharmaceutically acceptable salt thereof, wherein R^1 is methylamine or ethylamine.
18. The compound of Claim 1, or a pharmaceutically acceptable salt thereof, wherein R^1 is an unsubstituted di- C_1 - C_6 alkylamine.
19. The compound of Claim 1 or 18, or a pharmaceutically acceptable salt thereof, wherein R^1 is di-methylamine or di-ethylamine.
20. The compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, wherein m is 1.

21. The compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, wherein m is 2.
22. The compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, wherein m is 3.
23. The compound of any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, wherein one R^2 is an unsubstituted C_1 - C_6 alkyl and any other R^2 , if present, is independently selected from the group consisting of halogen, a substituted or unsubstituted C_1 - C_6 alkyl, a substituted or unsubstituted C_1 - C_6 haloalkyl and a substituted or unsubstituted C_3 - C_6 cycloalkyl.
24. The compound of any one of Claims 1-22, or a pharmaceutically acceptable salt thereof, wherein each R^2 is independently an unsubstituted C_1 - C_6 alkyl.
25. The compound of any one of Claims 1-19, 23 or 24, or a pharmaceutically acceptable salt thereof, wherein m is 2; and each R^2 is an unsubstituted methyl.
26. The compound of any one of Claims 1-19, or a pharmaceutically acceptable salt thereof, wherein m is 0.
27. The compound of any one of Claims 1-19 or 21-22, or a pharmaceutically acceptable salt thereof, wherein two R^2 groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted C_3 - C_6 cycloalkyl.
28. The compound of any one of Claims 1-19, 21-22 or 27, or a pharmaceutically acceptable salt thereof, wherein two R^2 groups taken together with the atom to which they are attached form an unsubstituted cyclopropyl.
29. The compound of any one of Claims 1-19, 21-22 or 27, or a pharmaceutically acceptable salt thereof, wherein two R^2 groups taken together with the atom to which they are attached form an unsubstituted cyclobutyl.
30. The compound of any one of Claims 1-19 or 21-22, or a pharmaceutically acceptable salt thereof, wherein two R^2 groups taken together with the atom(s) to which they are attached form a substituted or unsubstituted 3 to 6 membered heterocyclyl.
31. The compound of any one of Claims 1-30, wherein R^3 is hydrogen.
32. The compound of any one of Claims 1-30, wherein R^3 is halogen.
33. The compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R^4 is NO_2 .

34. The compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R^4 is cyano.

35. The compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R^4 is halogen.

36. The compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R^4 is an unsubstituted C_1 - C_6 haloalkyl.

37. The compound of any one of Claims 1-32 or 36, or a pharmaceutically acceptable salt thereof, wherein R^4 is $-CF_3$.

38. The compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R^4 is $S(O)R^6$.

39. The compound of any one of Claims 1-32, or a pharmaceutically acceptable salt thereof, wherein R^4 is SO_2R^6 .

40. The compound of any one of Claims 1-32 or 38-39, or a pharmaceutically acceptable salt thereof, wherein R^6 is a substituted or unsubstituted C_1 - C_6 alkyl.

41. The compound of any one of Claims 1-32 or 38-39, or a pharmaceutically acceptable salt thereof, wherein R^6 is a substituted or unsubstituted C_3 - C_6 cycloalkyl.

42. The compound of any one of Claims 1-32 or 38-39, or a pharmaceutically acceptable salt thereof, wherein R^6 is a substituted or unsubstituted C_1 - C_6 haloalkyl.

43. The compound of any one of Claims 38-39 or 42, or a pharmaceutically acceptable salt thereof, wherein R^6 is $-CF_3$.

44. The compound of any one of Claims 1-43, or a pharmaceutically acceptable salt thereof, wherein R^5 is a substituted or unsubstituted C_1 - C_6 alkylene, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-O-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-N(C_1-C_6 \text{ alkyl})-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-NH-Het-$, or a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-N(C_1-C_6 \text{ alkyl})-Het-$.

45. The compound of any one of Claims 1-43, or a pharmaceutically acceptable salt thereof, wherein R^5 is a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-Het-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-Het-O-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-Het-NH-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-Het-N(C_1-C_6 \text{ alkyl})-$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})-(C=O)-O-$, a substituted or unsubstituted $-(C_1-C_6$

alkylene)-Het-(C=O)-O-, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})\text{-Het-(C=O)-NH-}$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})\text{-Het-(C=O)-N(C}_1\text{-C}_6 \text{ alkyl)-}$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})\text{-Het-(C=O)-N(C}_3\text{-C}_6 \text{ cycloalkyl)-}$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})\text{-N(C}_3\text{-C}_6 \text{ cycloalkyl)-}$, a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})\text{-Het-N(C}_3\text{-C}_6 \text{ cycloalkyl)-}$ or a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})\text{-N(C}_3\text{-C}_6 \text{ cycloalkyl)-Het-}$.

46. The compound of Claim 45, or a pharmaceutically acceptable salt thereof, wherein Het is a substituted or unsubstituted azetidiny, pyrrolidiny, piperidiny, or piperaziny.

47. The compound of any one of Claims 1-46, or a pharmaceutically acceptable salt thereof, wherein X^1 is $-O-$.

48. The compound of any one of Claims 1-46, or a pharmaceutically acceptable salt thereof, wherein X^1 is $-NH-$.


49. The compound of any one of Claims 1-48, or a pharmaceutically acceptable salt thereof, wherein R^7 is absent.


50. The compound of any one of Claims 1-48, or a pharmaceutically acceptable salt thereof, wherein R^7 is a substituted or unsubstituted C_1-C_6 alkylene.


51. The compound of any one of Claims 1-48, or a pharmaceutically acceptable salt thereof, wherein R^7 is $-(C=O)-$, $-(C=S)-$, $-(C=O)-NH-$, $-(C=O)-N(C_1-C_6 \text{ alkyl})-$, $-(C=O)-N(C_3-C_6 \text{ cycloalkyl})-$, $-(C=O)-O-$ or $-(C=S)-NH-$.

52. The compound of any one of Claims 1-48, or a pharmaceutically acceptable salt thereof, wherein R^7 is a substituted or unsubstituted $-(C_1-C_6 \text{ alkylene})\text{-NH-}$.

53. The compound of any one of Claims 1-48, or a pharmaceutically acceptable salt thereof, wherein R^5 and R^7 are selected such that $-R^5-R^7-$ is selected from:







54. The compound of any one of Claims 1-53, or a pharmaceutically acceptable salt thereof, wherein R^8 is absent.

55. The compound of any one of Claims 1-53, or a pharmaceutically acceptable salt thereof, wherein R^8 is a substituted or unsubstituted C_1 - C_6 alkylene.

56. The compound of any one of Claims 1-53, or a pharmaceutically acceptable salt thereof, wherein R^8 is a substituted or unsubstituted $-(C_1$ - C_6 alkylene)-(C_6 - C_{12} aryl)-, a substituted or unsubstituted $-(C_1$ - C_6 alkylene)-(C_3 - C_{10} cycloalkyl)-, a substituted or unsubstituted $-(C_1$ - C_6 alkylene)-(C_3 - C_{10} heterocyclyl)-, or a substituted or unsubstituted $-(C_1$ - C_6 alkylene)-(5 to 10 membered heteroaryl)-.

57. The compound of any one of Claims 1-56, or a pharmaceutically acceptable salt thereof, wherein n is 1, 2, 3, 4 or 5.


58. The compound of any one of Claims 1-56, or a pharmaceutically acceptable salt thereof, wherein n is 0.

59. The compound of any one of Claims 1-58, or a pharmaceutically acceptable salt thereof, wherein R⁹ is a substituted or unsubstituted C₁-C₁₀ alkylene, a substituted or unsubstituted -(C₁-C₆ alkylene)-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-, or a substituted or unsubstituted -(C₁-C₆ alkylene)-(C=O)NH-.


60. The compound of any one of Claims 1-58, or a pharmaceutically acceptable salt thereof, wherein R⁹ is a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH(C=O)-(C₁-C₆ alkylene)-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH(C=O)-(C₁-C₆ alkylene)-O-, or a substituted or unsubstituted -(C₁-C₆ alkylene)-NH(C=O)-(C₁-C₆ alkylene)-.


61. The compound of any one of Claims 1-58, or a pharmaceutically acceptable salt thereof, wherein R⁹ is a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-NH(C=O)-(C₁-C₆ alkylene)-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-NH(C=O)-(C₁-C₆ alkylene)-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-NH(C=O)-(C₁-C₆ alkylene)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-(C=O)NH-(C₁-C₆ alkylene)-, a substituted or unsubstituted -(C₁-C₆ alkylene)-(C=O)NH-(C₁-C₆ alkylene)-NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-(C=O)NH-(C₁-C₆ alkylene)-O-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH(C=O)-(C₁-C₆ alkylene)-(C=O)NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-(C=O)NH-, a substituted or unsubstituted -(C₁-C₆ alkylene)-NH-(C₁-C₆ alkylene)-(C=O)NH-(C₁-C₆ alkylene)- or a substituted or an unsubstituted -(C₁-C₆ alkylene)-C≡C-.

62. The compound of any one of Claims 1-61, or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is selected from the group consisting of:



63. The compound of any one of Claims 1-60, or a pharmaceutically acceptable salt thereof, wherein R¹⁰ is selected from the group consisting of:





64. The compound of Claim 1, wherein the compound is selected from the group consisting of the compounds of Examples 1 through 218 as listed in Table A, or a pharmaceutically acceptable salt of any of the foregoing.

65. A pharmaceutical composition comprising an effective amount of the compound of any one of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, excipient or combination thereof.

66. A method for treating a cancer or a tumor comprising administering an effective amount of a compound of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65, to a subject having the cancer or the tumor, wherein the cancer or the tumor is selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct

cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

67. A method for inhibiting replication of a malignant growth or a tumor comprising contacting the growth or the tumor with an effective amount of a compound of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65, wherein the malignant growth or tumor selected from an Ewings's tumor and a Wilm's tumor, or the malignant growth of tumor is due to a cancer selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma.

68. A method for treating a cancer comprising contacting a malignant growth or a tumor with an effective amount of a compound of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65, wherein the malignant growth or tumor selected from an Ewings's tumor and a Wilm's tumor, or the malignant growth of tumor is due to a cancer selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma or an osteosarcoma.

69. A method for inhibiting the activity of a Bcl-2 protein and/or a Bcl-xL protein, comprising providing an effective amount of a compound of any one of Claims 1-64, or a

pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65 to a cancer cell or a tumor, wherein the cancer cell or the tumor is from a cancer selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

70. A method for inhibiting the activity of a Bcl-2 protein and/or a Bcl-xL protein in a subject, comprising providing an effective amount of a compound of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65 to the subject having a cancer or a tumor, wherein the cancer or the tumor is selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

71. Use of an effective amount of a compound of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65 in the manufacture of a medicament for treating a cancer or a tumor, wherein the cancer or the tumor is selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's

lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

72. Use of an effective amount of a compound of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65 in the manufacture of a medicament for inhibiting replication of a malignant growth or a tumor, wherein the malignant growth or the tumor is due to a cancer selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.

73. Use of an effective amount of a compound of any one of Claims 1-64, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition of Claim 65 in the manufacture of a medicament for treating a malignant growth or a tumor, wherein the malignant growth or the tumor is due to a cancer selected from a bladder cancer, a brain cancer, a breast cancer, a bone marrow cancer, a cervical cancer, a colorectal cancer, an esophageal cancer, a hepatocellular cancer, a lymphoblastic leukemia, a follicular lymphoma, a lymphoid malignancy of T-cell or B-cell origin, a melanoma, a myelogenous leukemia, a Hodgkin's lymphoma, a Non-Hodgkin's lymphoma, a head and neck cancer (including oral cancer), an ovarian cancer, a non-small cell lung cancer, a chronic lymphocytic leukemia, a myeloma, a prostate cancer, a small cell lung cancer, a spleen cancer, a polycythemia vera, a thyroid cancer, an endometrial cancer, a stomach cancer, a gallbladder cancer, a bile duct cancer, a testicular cancer, a neuroblastoma, an osteosarcoma, an Ewings's tumor and a Wilm's tumor.